Pt. ID | Gender | Age | Menopausal status | Breast cancer diagnosis | Stage | CDK4/6i | Endocrine partner | Initial cycle with palbociclib versus later cycle | Prior treatment for metastatic cancer |
1 | Female | Early 70s | Postmenopausal | Hormone receptor positive breast cancer | IV | Palbociclib | Fulvestrant | Initial | None |
2 | Female | Late 40s | Premenopausal | Hormone receptor positive breast cancer | IV | Palbociclib | Tamoxifen+ goserelin | Later | None |
3 | Female | Early 50s | Premenopausal | Hormone receptor positive breast cancer | IV | Palbociclib | Letrozole+ leuprolide | Later | Paclitaxel |
4 | Female | Early 60s | Postmenopausal | Hormone receptor positive breast cancer | IV | Palbociclib | Letrozole | Later | None |
5 | Female | Early 80s | Postmenopausal | Hormone receptor positive breast cancer | IV | Palbociclib | Letrozole | Later | None |
6 | Female | Late 50s | Postmenopausal | Hormone receptor positive breast cancer | IV | Palbociclib | Letrozole | Later | None |
7 | Female | Mid 50s | Postmenopausal | Hormone receptor positive breast cancer | IV | Palbociclib | Letrozole | Later | None |
8 | Female | Mid 70s | Postmenopausal | Hormone receptor positive breast cancer | IV | Palbociclib | Fulvestrant | Initial | None |
CDK 4/6i, cyclin-dependent kinase 4/6 inhibitors; Pt, patient.